Clinical Cancer Research, Vol 1, Issue 8 859-864, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors

IA Lorimer, CJ Wikstrand, SK Batra, DD Bigner and I Pastan
Laboratory of Molecular Biology, Division of Cancer Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.

Human cancers arise from a series of mutations, many of which direct the expression of mutant proteins with altered functions. These aberrant proteins are attractive targets for new therapeutic agents. One such protein is a mutant epidermal growth factor receptor (EGFRvIII) that has an in-frame deletion near the NH2 terminus of its extracellular domain. This protein was first identified in human gliomas, but has also been shown to be present in lung and breast carcinomas. The deletion results in a receptor with constitutive tyrosine kinase activity that enhances the tumorigenicity of glioblastomas in vivo. The deletion also creates a tumor-specific cell-surface sequence at the deletion junction. Three specific anti-EGFRvIII mAbs have been isolated following immunization with a mixture of a deletion junction synthetic peptide and EGFRvIII as present on cell membranes. We have constructed immunotoxins by conjugating a modified version of Pseudomonas exotoxin A to these mAbs. Immunotoxins were tested on cells that had been transfected with cDNA for the EGFRvIII receptor and expressed receptor protein at 5 x 10(5) receptors/cell. All three immunotoxins were cytotoxic to these cells, with 50% inhibition of protein synthesis occurring in a 15-50 pM range. The immunotoxins specifically targeted EGFRvIII, as their cytotoxicity could be blocked by their respective free antibody. They showed little or no cytotoxicity to cells expressing high levels of normal epidermal growth factor receptors, demonstrating that they are able to discriminate between cells expressing the mutant receptor and those expressing the wild-type receptor. Immunotoxins targeted to mutant epidermal growth factor receptors are promising candidates for further development as tumor cell-specific therapeutic agents.

This article has been cited by other articles:

				F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes & Dev., November 1, 2007; 21(21): 2683 - 2710. [Abstract] [Full Text] [PDF]

				C. Bianco, R. Bianco, G. Tortora, V. Damiano, P. Guerrieri, P. Montemaggi, J. Mendelsohn, S. De Placido, A. R. Bianco, and F. Ciardiello Antitumor Activity of Combined Treatment of Human Cancer Cells with Ionizing Radiation and Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225 plus Type I Protein Kinase A Antisense Oligonucleotide Clin. Cancer Res., November 1, 2000; 6(11): 4343 - 4350. [Abstract] [Full Text] [PDF]

				F. Ciardiello, R. Bianco, V. Damiano, G. Fontanini, R. Caputo, G. Pomatico, Sabino De Placido, A. R. Bianco, J. Mendelsohn, and G. Tortora Antiangiogenic and Antitumor Activity of Anti-Epidermal Growth Factor Receptor C225 Monoclonal Antibody in Combination with Vascular Endothelial Growth Factor Antisense Oligonucleotide in Human GEO Colon Cancer Cells Clin. Cancer Res., September 1, 2000; 6(9): 3739 - 3747. [Abstract] [Full Text]

				R. Beers, P. Chowdhury, D. Bigner, and I. Pastan Immunotoxins with Increased Activity against Epidermal Growth Factor Receptor vIII-expressing Cells Produced by Antibody Phage Display Clin. Cancer Res., July 1, 2000; 6(7): 2835 - 2843. [Abstract] [Full Text]

				M. R. Emmert-Buck, R. L. Strausberg, D. B. Krizman, M. F. Bonaldo, R. F. Bonner, D. G. Bostwick, M. R. Brown, K. H. Buetow, R. F. Chuaqui, K. A. Cole, et al. Molecular Profiling of Clinical Tissue Specimens: Feasibility and Applications J. Mol. Diagn., May 1, 2000; 2(2): 60 - 66. [Full Text]

				M. R. Emmert-Buck, R. L. Strausberg, D. B. Krizman, M. F. Bonaldo, R. F. Bonner, D. G. Bostwick, M. R. Brown, K. H. Buetow, R. F. Chuaqui, K. A. Cole, et al. Molecular Profiling of Clinical Tissue Specimens : Feasibility and Applications Am. J. Pathol., April 1, 2000; 156(4): 1109 - 1115. [Full Text] [PDF]

				G. E. Archer, J. H. Sampson, I. A. J. Lorimer, R. E. McLendon, C.-T. Kuan, A. H. Friedman, H. S. Friedman, I. H. Pastan, and D. D. Bigner Regional Treatment of Epidermal Growth Factor Receptor vIII-expressing Neoplastic Meningitis with a Single-Chain Immunotoxin, MR-1 Clin. Cancer Res., September 1, 1999; 5(9): 2646 - 2652. [Abstract] [Full Text] [PDF]

				W. Debinski, D. M. Gibo, S. W. Hulet, J. R. Connor, and G. Y. Gillespie Receptor for Interleukin 13 Is a Marker and Therapeutic Target for Human High-Grade Gliomas Clin. Cancer Res., May 1, 1999; 5(5): 985 - 990. [Abstract] [Full Text] [PDF]

				F. Ciardiello, R. Bianco, V. Damiano, S. De Lorenzo, S. Pepe, S. De Placido, Z. Fan, J. Mendelsohn, A. R. Bianco, and G. Tortora Antitumor Activity of Sequential Treatment with Topotecan and Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225 Clin. Cancer Res., April 1, 1999; 5(4): 909 - 916. [Abstract] [Full Text] [PDF]

				I. A. J. Lorimer, A. Keppler-Hafkemeyer, R. A. Beers, C. N. Pegram, D. D. Bigner, and I. Pastan Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display PNAS, December 10, 1996; 93(25): 14815 - 14820. [Abstract] [Full Text] [PDF]